SACUBITRIL VALSARTAN
Cancer, Therapy-Related
Silesian Centre for Heart DiseasesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Cancer, Therapy-Related cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | BB |
Capecitabine Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | BB |
Irinotecan Ludwig-Maximilians - University of Munich | Phase 2 | BB |
Sorafenib The University of Hong Kong | Phase 2 | B |
Cetuximab Ludwig-Maximilians - University of Munich | Phase 2 | B |
View all 21 →
Same molecule, other indications
SACUBITRIL VALSARTAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →